{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T10:52:12Z","timestamp":1788778332564,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-025-04046-1","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T16:51:49Z","timestamp":1763398309000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["SGLT2 inhibitors and their role in reducing mortality among cancer patients with type 2 diabetes undergoing immune checkpoint inhibitor therapy"],"prefix":"10.1007","volume":"16","author":[{"given":"Fabiana","family":"Luc\u00e0","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Parrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"issue":"1","key":"4046_CR1","first-page":"2","volume":"10","author":"MG Perelman","year":"2024","unstructured":"Perelman MG, Brzezinski RY, Waissengrin B, Leshem Y, Bainhoren O, Rubinstein TA, et al. Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors. Cardiooncology. 2024;10(1):2.","journal-title":"Cardiooncology"},{"issue":"2","key":"4046_CR2","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMra1703481","volume":"378","author":"MA Postow","year":"2018","unstructured":"Postow MA, Sidlow R, Hellmann MD. Immune-Related adverse events associated with immune checkpoint Blockade. N Engl J Med. 2018;378(2):158\u201368.","journal-title":"N Engl J Med"},{"issue":"9","key":"4046_CR3","doi-asserted-by":"publisher","first-page":"e447","DOI":"10.1016\/S1470-2045(18)30457-1","volume":"19","author":"AR Lyon","year":"2018","unstructured":"Lyon AR, Yousaf N, Battisti NML, Moslehi J, Larkin J. Immune checkpoint inhibitors and cardiovascular toxicity. Lancet Oncol. 2018;19(9):e447\u201358.","journal-title":"Lancet Oncol"},{"issue":"10","key":"4046_CR4","first-page":"711","volume":"25","author":"ML Canale","year":"2024","unstructured":"Canale ML, Greco A, Inno A, Tedeschi A, De Biasio M, Oliva S, et al. [Atherosclerosis, cancer and immune checkpoint inhibitors]. G Ital Cardiol (Rome). 2024;25(10):711\u20139.","journal-title":"G Ital Cardiol (Rome)"},{"issue":"9","key":"4046_CR5","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1159\/000516671","volume":"99","author":"O Jacobi","year":"2021","unstructured":"Jacobi O, Landman Y, Reinhorn D, Icht O, Sternschuss M, Rotem O, et al. The relationship of diabetes mellitus to efficacy of immune checkpoint inhibitors in patients with advanced Non-Small cell lung cancer. Oncology. 2021;99(9):555\u201361.","journal-title":"Oncology"},{"issue":"3","key":"4046_CR6","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1007\/s12020-021-02884-x","volume":"74","author":"N Mili","year":"2021","unstructured":"Mili N, Paschou SA, Goulis DG, Dimopoulos MA, Lambrinoudaki I, Psaltopoulou T. Obesity, metabolic syndrome, and cancer: pathophysiological and therapeutic associations. Endocrine. 2021;74(3):478\u201397.","journal-title":"Endocrine"},{"issue":"10296","key":"4046_CR7","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/S0140-6736(21)00536-5","volume":"398","author":"E Brown","year":"2021","unstructured":"Brown E, Heerspink HJL, Cuthbertson DJ, Wilding JPH. SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications. Lancet. 2021;398(10296):262\u201376.","journal-title":"Lancet"},{"issue":"25","key":"4046_CR8","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1016\/j.jacc.2023.04.034","volume":"81","author":"MS Usman","year":"2023","unstructured":"Usman MS, Siddiqi TJ, Anker SD, Bakris GL, Bhatt DL, Filippatos G, et al. Effect of SGLT2 inhibitors on cardiovascular outcomes across various patient populations. JACC. 2023;81(25):2377\u201387.","journal-title":"JACC"},{"issue":"3Part2","key":"4046_CR9","first-page":"287","volume":"2","author":"Y Kubota","year":"2022","unstructured":"Kubota Y, Shimizu W. Clinical benefits of Sodium\u2013Glucose cotransporter 2 inhibitors and the mechanisms underlying their cardiovascular effects. JACC: Asia. 2022;2(3Part2):287\u201393.","journal-title":"JACC: Asia"},{"key":"4046_CR10","doi-asserted-by":"crossref","unstructured":"Kaplinsky E. DAPA-HF trial: Dapagliflozin evolves from a glucose-lowering agent to a therapy for heart failure. Drugs Context. 2020;9.","DOI":"10.7573\/dic.2019-11-3"},{"issue":"4","key":"4046_CR11","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1161\/CIRCULATIONAHA.120.051783","volume":"143","author":"M Packer","year":"2021","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Ferreira JP, Pocock SJ, et al. Effect of empagliflozin on the clinical stability of patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial. Circulation. 2021;143(4):326\u201336.","journal-title":"Circulation"},{"issue":"8","key":"4046_CR12","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1093\/ckj\/sfad082","volume":"16","author":"B Fern\u00e1ndez-Fernandez","year":"2023","unstructured":"Fern\u00e1ndez-Fernandez B, Sarafidis P, Soler MJ, Ortiz A. EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors. Clin Kidney J. 2023;16(8):1187\u201398.","journal-title":"Clin Kidney J"},{"issue":"5","key":"4046_CR13","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1111\/jgh.16498","volume":"39","author":"CH Chiang","year":"2024","unstructured":"Chiang CH, Chiang CH, Hsia YP, Jaroenlapnopparat A, Horng CS, Wong KY, et al. The impact of sodium-glucose cotransporter-2 inhibitors on outcome of patients with diabetes mellitus and colorectal cancer. J Gastroenterol Hepatol. 2024;39(5):902\u20137.","journal-title":"J Gastroenterol Hepatol"},{"issue":"8","key":"4046_CR14","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1038\/s41416-023-02177-2","volume":"128","author":"J Luo","year":"2023","unstructured":"Luo J, Hendryx M, Dong Y. Sodium-glucose cotransporter 2 (SGLT2) inhibitors and non-small cell lung cancer survival. Br J Cancer. 2023;128(8):1541\u20137.","journal-title":"Br J Cancer"},{"issue":"2","key":"4046_CR15","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jaccao.2024.01.007","volume":"6","author":"MS Dabour","year":"2024","unstructured":"Dabour MS, George MY, Daniel MR, Blaes AH, Zordoky BN. The cardioprotective and anticancer effects of SGLT2 inhibitors: JACC: cardiooncology State-of-the-Art review. JACC CardioOncol. 2024;6(2):159\u201382.","journal-title":"JACC CardioOncol"},{"issue":"1","key":"4046_CR16","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/imr.13247","volume":"318","author":"N Singh","year":"2023","unstructured":"Singh N, Hocking AM, Buckner JH. Immune-related adverse events after immune check point inhibitors: Understanding the intersection with autoimmunity. Immunol Rev. 2023;318(1):81\u20138.","journal-title":"Immunol Rev"},{"key":"4046_CR17","doi-asserted-by":"crossref","unstructured":"Moslehi J, Lichtman AH, Sharpe AH, Galluzzi L, Kitsis RN. Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms. J Clin Invest. 2021;131(5).","DOI":"10.1172\/JCI145186"},{"issue":"6","key":"4046_CR18","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.jacc.2021.11.048","volume":"79","author":"JT Vuong","year":"2022","unstructured":"Vuong JT, Stein-Merlob AF, Nayeri A, Sallam T, Neilan TG, Yang EH. Immune checkpoint therapies and atherosclerosis: mechanisms and clinical implications: JACC State-of-the-Art review. J Am Coll Cardiol. 2022;79(6):577\u201393.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"4046_CR19","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s11883-024-01241-3","volume":"26","author":"A d\u2019Aiello","year":"2024","unstructured":"d\u2019Aiello A, Filomia S, Brecciaroli M, Sanna T, Pedicino D, Liuzzo G. Targeting inflammatory pathways in atherosclerosis: exploring new opportunities for treatment. Curr Atheroscler Rep. 2024;26(12):707\u201319.","journal-title":"Curr Atheroscler Rep"},{"issue":"16","key":"4046_CR20","doi-asserted-by":"publisher","first-page":"5866","DOI":"10.18632\/aging.102175","volume":"11","author":"\u00c1 Garc\u00eda-Ropero","year":"2019","unstructured":"Garc\u00eda-Ropero \u00c1, Santos-Gallego CG, Badimon JJ. The anti-inflammatory effects of SGLT inhibitors. Aging. 2019;11(16):5866\u20137.","journal-title":"Aging"},{"key":"4046_CR21","doi-asserted-by":"crossref","unstructured":"Abrignani MG, Luc\u00e0 F, Abrignani V, Nucara M, Grosseto D, Lestuzzi C et al. Risk factors and prevention of cancer and cvds: A chicken and egg situation. J Clin Med. 2025;14(9).","DOI":"10.3390\/jcm14093083"},{"key":"4046_CR22","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3389\/fendo.2020.00060","volume":"11","author":"H Tao","year":"2020","unstructured":"Tao H, O\u2019Neil A, Choi Y, Wang W, Wang J, Wang Y, et al. Pre- and Post-diagnosis diabetes as a risk factor for All-Cause and cancer-Specific mortality in Breast, Prostate, and colorectal cancer survivors: a prospective cohort study. Front Endocrinol (Lausanne). 2020;11:60.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"4046_CR23","doi-asserted-by":"crossref","unstructured":"Shahid RK, Ahmed S, Le D, Yadav S. Diabetes and cancer: Risk, Challenges, management and outcomes. Cancers (Basel). 2021;13(22).","DOI":"10.3390\/cancers13225735"},{"issue":"1","key":"4046_CR24","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1186\/s13046-019-1309-6","volume":"38","author":"W Li","year":"2019","unstructured":"Li W, Zhang X, Sang H, Zhou Y, Shang C, Wang Y, et al. Effects of hyperglycemia on the progression of tumor diseases. J Exp Clin Cancer Res. 2019;38(1):327.","journal-title":"J Exp Clin Cancer Res"},{"key":"4046_CR25","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s40170-019-0203-1","volume":"7","author":"AR Nasiri","year":"2019","unstructured":"Nasiri AR, Rodrigues MR, Li Z, Leitner BP, Perry RJ. SGLT2 Inhibition slows tumor growth in mice by reversing hyperinsulinemia. Cancer Metab. 2019;7:10.","journal-title":"Cancer Metab"},{"issue":"10","key":"4046_CR26","doi-asserted-by":"publisher","first-page":"e333","DOI":"10.1093\/ehjci\/jeac106","volume":"23","author":"AR Lyon","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European hematology association (EHA), the European society for therapeutic radiology and oncology (ESTRO) and the international Cardio-Oncology society (IC-OS). Eur Heart J Cardiovasc Imaging. 2022;23(10):e333\u2013465.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"1","key":"4046_CR27","first-page":"50","volume":"11","author":"T Reshadmanesh","year":"2025","unstructured":"Reshadmanesh T, Mohebi R, Behnoush AH, Reshadmanesh A, Khalaji A, Norouzi M, et al. The effects of sodium-glucose cotransporter-2 inhibitors in chemotherapy-induced cardiotoxicity and mortality in patients with cancer: a systematic review and meta-analysis. Cardiooncology. 2025;11(1):50.","journal-title":"Cardiooncology"},{"issue":"6","key":"4046_CR28","doi-asserted-by":"publisher","first-page":"857","DOI":"10.3390\/ph18060857","volume":"18","author":"AM Zebrowska","year":"2025","unstructured":"Zebrowska AM, Borowiec A. Potential new applications of Sodium\u2013Glucose Cotransporter-2 inhibitors across the continuum of Cancer-Related cardiovascular toxicity. Pharmaceuticals. 2025;18(6):857.","journal-title":"Pharmaceuticals"},{"issue":"5","key":"4046_CR29","first-page":"631","volume":"6","author":"Z Raisi-Estabragh","year":"2024","unstructured":"Raisi-Estabragh Z, Murphy AC, Ramalingam S, Scherrer-Crosbie M, Lopez-Fernandez T, Reynolds KL, et al. Cardiovasc Considerations before Cancer Therapy JACC: CardioOncology. 2024;6(5):631\u201354.","journal-title":"Cardiovasc Considerations before Cancer Therapy JACC: CardioOncology"},{"issue":"2","key":"4046_CR30","doi-asserted-by":"publisher","first-page":"164","DOI":"10.2174\/1871520616666161031143301","volume":"17","author":"L Schwartz","year":"2017","unstructured":"Schwartz L, Supuran CT, Alfarouk KO. The Warburg effect and the hallmarks of cancer. Anticancer Agents Med Chem. 2017;17(2):164\u201370.","journal-title":"Anticancer Agents Med Chem"},{"key":"4046_CR31","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.freeradbiomed.2024.01.015","volume":"213","author":"C Luna-Marco","year":"2024","unstructured":"Luna-Marco C, Iannantuoni F, Hermo-Argibay A, Devos D, Salazar JD, V\u00edctor VM, et al. Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists through effects on mitochondrial function and oxidative stress. Free Radic Biol Med. 2024;213:19\u201335.","journal-title":"Free Radic Biol Med"},{"issue":"2","key":"4046_CR32","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1002\/ehf2.15103","volume":"12","author":"L Qu","year":"2025","unstructured":"Qu L, Duan X, Chen H. The effects of sodium\u2013glucose cotransporter 2 inhibitors on the \u2018forgotten\u2019 right ventricle. ESC Heart Fail. 2025;12(2):1045\u201358.","journal-title":"ESC Heart Fail"},{"issue":"1","key":"4046_CR33","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1186\/s13046-021-02041-2","volume":"40","author":"W Jiang","year":"2021","unstructured":"Jiang W, Hu JW, He XR, Jin WL, He XY. Statins: a repurposed drug to fight cancer. J Exp Clin Cancer Res. 2021;40(1):241.","journal-title":"J Exp Clin Cancer Res"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-04046-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-025-04046-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-025-04046-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T16:51:51Z","timestamp":1763398311000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-025-04046-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4046"],"URL":"https:\/\/doi.org\/10.1007\/s12672-025-04046-1","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,17]]},"assertion":[{"value":"7 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2109"}}